Russia's Biocad completes registration of generic of glatiramer acetate

Russian drugmaker Biocad has announced that it has successfully completed registration of a generic of glatiramer acetate, a drug for the treatment of multiple sclerosis, reports The Pharma Letter’s local correspondent.

According to the company, prices for its drug will be 30% less than those for the original drug, trade name Copaxone, which is produced by Israel’s Teva Pharmaceutical Industries (NYSE: TEVA).

Development of glatiramer acetate began in 2012. The drug became the subject of a two-year Phase III clinical study, which proved it equivalence to the original drug, in terms of all indicators of efficacy and safety. The volume of investments in conducting clinical studies amounted to 400 million roubles ($6.1 million).